Kidney allograft rejection is associated with an imbalance of B cells, regulatory T cells and differentiated CD28-CD8+ T cells: analysis of a cohort of 1095 graft biopsies.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 25 01 2023
accepted: 06 04 2023
medline: 15 5 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: epublish

Résumé

The human immune system contains cells with either effector/memory or regulatory functions. Besides the well-established CD4+CD25hiCD127lo regulatory T cells (Tregs), we and others have shown that B cells can also have regulatory functions since their frequency and number are increased in kidney graft tolerance and B cell depletion as induction therapy may lead to acute rejection. On the other hand, we have shown that CD28-CD8+ T cells represent a subpopulation with potent effector/memory functions. In the current study, we tested the hypothesis that kidney allograft rejection may be linked to an imbalance of effector/memory and regulatory immune cells. Based on a large cohort of more than 1000 kidney graft biopsies with concomitant peripheral blood lymphocyte phenotyping, we investigated the association between kidney graft rejection and the percentage and absolute number of circulating B cells, Tregs, as well as the ratio of B cells to CD28-CD8+ T cells and the ratio of CD28-CD8+ T cells to Tregs. Kidney graft biopsies were interpreted according to the Banff classification and divided into 5 biopsies groups: 1) normal/subnormal, 2) interstitial fibrosis and tubular atrophy grade 2/3 (IFTA), 3) antibody-mediated rejection (ABMR), 4) T cell mediated-rejection (TCMR), and 5) borderline rejection. We compared group 1 with the other groups as well as with a combined group 3, 4, and 5 (rejection of all types) using multivariable linear mixed models. We found that compared to normal/subnormal biopsies, rejection of all types was marginally associated with a decrease in the percentage of circulating B cells (p=0.06) and significantly associated with an increase in the ratio of CD28-CD8+ T cells to Tregs (p=0.01). Moreover, ABMR, TCMR (p=0.007), and rejection of all types (p=0.0003) were significantly associated with a decrease in the ratio of B cells to CD28-CD8+ T cells compared to normal/subnormal biopsies. Taken together, our results show that kidney allograft rejection is associated with an imbalance between immune cells with effector/memory functions and those with regulatory properties.

Identifiants

pubmed: 37168864
doi: 10.3389/fimmu.2023.1151127
pmc: PMC10164960
doi:

Substances chimiques

Antibodies 0
CD28 Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1151127

Informations de copyright

Copyright © 2023 Mai, Degauque, Lorent, Rimbert, Renaudin, Danger, Kerleau, Tilly, Vivet, Le Bot, Delbos, Walencik, Giral and Brouard.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Transplant. 2015 Sep;15(9):2288-300
pubmed: 26234373
Immunology. 2011 Sep;134(1):17-32
pubmed: 21711350
Am J Transplant. 2018 Feb;18(2):293-307
pubmed: 29243394
JCI Insight. 2021 Nov 8;6(21):
pubmed: 34609965
Clin Exp Immunol. 2019 Jun;196(3):403-414
pubmed: 30712266
Am J Transplant. 2017 Jan;17(1):28-41
pubmed: 27862883
J Am Soc Nephrol. 2014 Jul;25(7):1575-85
pubmed: 24610932
Front Immunol. 2021 Jul 21;12:674016
pubmed: 34367138
N Engl J Med. 2009 Jun 18;360(25):2683-5
pubmed: 19535812
Am J Transplant. 2020 Apr;20(4):942-953
pubmed: 31715060
Transplantation. 2000 Feb 15;69(3):366-71
pubmed: 10706044
Transplantation. 2014 Dec 15;98(11):1213-8
pubmed: 25083613
Kidney Int. 2022 May;101(5):1003-1016
pubmed: 35090879
J Clin Invest. 2010 Jun;120(6):1836-47
pubmed: 20501946
J Immunol. 2005 Jun 1;174(11):7292-301
pubmed: 15905576
J Am Soc Nephrol. 2020 Apr;31(4):876-891
pubmed: 32165419
BMC Immunol. 2019 Aug 5;20(1):26
pubmed: 31382877
Ther Drug Monit. 2016 Apr;38 Suppl 1:S36-42
pubmed: 26977998
Kidney Int. 2010 Sep;78(5):503-13
pubmed: 20531452
Am J Transplant. 2011 Jan;11(1):22-33
pubmed: 21070604
Front Immunol. 2021 May 24;12:683926
pubmed: 34108975
Immunity. 2010 Jan 29;32(1):129-40
pubmed: 20079667
Am J Transplant. 2015 May;15(5):1384-91
pubmed: 25808898
Immun Ageing. 2021 Nov 8;18(1):43
pubmed: 34749733
Biometrics. 1982 Dec;38(4):963-74
pubmed: 7168798
Transpl Int. 2008 Jan;21(1):65-73
pubmed: 17887959
Transpl Int. 2016 May;29(5):540-8
pubmed: 26839984
Mol Med. 2012 Jul 18;18:733-43
pubmed: 22252714
EBioMedicine. 2022 Sep;83:104226
pubmed: 35988467
Immunity. 2014 Dec 18;41(6):1040-51
pubmed: 25484301
J Am Soc Nephrol. 2015 Oct;26(10):2588-98
pubmed: 25644114
BMC Nephrol. 2021 May 17;22(1):180
pubmed: 33993874
Front Immunol. 2021 Apr 29;12:611795
pubmed: 33995344
Cancer Res. 2013 Apr 15;73(8):2468-79
pubmed: 23384943
Front Immunol. 2018 Dec 21;9:3034
pubmed: 30622536
Am J Transplant. 2014 Nov;14(11):2460-6
pubmed: 25323029
Transplantation. 2006 Feb 15;81(3):398-407
pubmed: 16477227
J Am Soc Nephrol. 2006 Jan;17(1):294-304
pubmed: 16338967
Transpl Int. 2007 Oct;20(10):845-55
pubmed: 17854443
N Engl J Med. 2010 Oct 7;363(15):1451-62
pubmed: 20925547
Transpl Immunol. 2020 Jun;60:101290
pubmed: 32240775
J Am Soc Nephrol. 2015 Aug;26(8):1795-805
pubmed: 25556168
Kidney Int. 2014 Mar;85(3):590-9
pubmed: 24284517
J Clin Invest. 2010 Jun;120(6):1848-61
pubmed: 20501943
Nat Immunol. 2002 Oct;3(10):944-50
pubmed: 12244307
Hum Immunol. 2010 May;71(5):442-50
pubmed: 20122976
Kidney Int. 2018 May;93(5):1154-1164
pubmed: 29455908
Nat Rev Nephrol. 2014 Jul;10(7):389-97
pubmed: 24846332
Kidney Int. 2017 Jan;91(1):183-195
pubmed: 28029430
Allergy. 2021 Sep;76(9):2699-2715
pubmed: 33544905
Int Immunopharmacol. 2020 Sep;86:106750
pubmed: 32652501
Nephrology (Carlton). 2017 Jul;22(7):505-512
pubmed: 27517975
J Clin Invest. 2003 Oct;112(7):1037-48
pubmed: 14523041

Auteurs

Hoa Le Mai (HL)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.

Nicolas Degauque (N)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.

Marine Lorent (M)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.

Marie Rimbert (M)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.
Laboratoire d'Immunologie, Centre d'ImmunoMonitorage Nantes-Atlantique (CIMNA), CHU Nantes, Nantes, France.

Karine Renaudin (K)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.
Service d'Anatomie et Cytologie Pathologiques, CHU Nantes, Nantes, France.

Richard Danger (R)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.

Clarisse Kerleau (C)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.

Gaelle Tilly (G)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.

Anaïs Vivet (A)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.

Sabine Le Bot (S)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.
Service de Néphrologie et Immunologie Clinique, CHU Nantes, Nantes, France.

Florent Delbos (F)

Etablissement Français du Sang (EFS), Nantes, France.

Alexandre Walencik (A)

Etablissement Français du Sang (EFS), Nantes, France.

Magali Giral (M)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.
Service de Néphrologie et Immunologie Clinique, CHU Nantes, Nantes, France.
Fondation Centaure (RTRS), Nantes, France.

Sophie Brouard (S)

Centre Hospitalier Universitaire (CHU) Nantes, Nantes Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Research in Transplantation and Translational Immunology, Unité mixte de recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France.
Fondation Centaure (RTRS), Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH